Evidence map›Paper›PMID 37529944›Full record

ArticleHuman vaccines & immunotherapeutics2023

The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C.

Yaru Shi, Katrina M Nolan, Robert L Burton, Tulin Shekar, Rocio D Murphy, Natalie Banniettis, Luwy Musey, Ulrike K Buchwald

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Genome sequences of 36Microbiology resource announcements · 2024
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Yaru ShiMerck & Co., Inc., Rahway, NJ, USA.
Katrina M NolanMerck & Co., Inc., Rahway, NJ, USA.
Robert L BurtonSunFire Biotechnologies LLC, Birmingham, AL, USA.
Tulin ShekarMerck & Co., Inc., Rahway, NJ, USA.
Rocio D MurphyMerck & Co., Inc., Rahway, NJ, USA.
Natalie BanniettisMerck & Co., Inc., Rahway, NJ, USA.
Luwy MuseyMerck & Co., Inc., Rahway, NJ, USA.
Ulrike K BuchwaldMerck & Co., Inc., Rahway, NJ, USA.
Merck & Co., Inc., Rahway, NJ, USA (United States) · USSunfire (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pneumococcal serogroups consist of structurally related serotypes, and serotype-specific antibodies can cross-react against other serotypes within the same serogroup. Cross-reactivity of vaccine-induced serotype 6A antibodies, and, to a lesser extent, serotype 6B antibodies, to serotype 6C has been demonstrated following receipt of the 13-valent pneumococcal conjugate vaccine (PCV13), which contains serotypes 6A and 6B. V114 is a 15-valent PCV containing the 13 PCV13 serotypes plus two additional serotypes, 22F and 33F. This study assessed cross-reactivity to serotype 6C in recipients of V114 and PCV13 as well as specificity of opsonophagocytic activity (OPA) responses in serogroup 6. Following receipt of V114 or PCV13, the observed OPA geometric mean titers to serotypes 6A, 6B, and 6C were comparable across both vaccination groups (post-single dose in adults ≥50 years of age [

Indexed as

Antibodies, BacterialPneumococcal InfectionsAdultChildHumansPneumococcal VaccinesSerogroupStreptococcus pneumoniaeVaccines, ConjugateAntibodies, BacterialPneumococcal VaccinesVaccines, Conjugate15-valent PCVcross-reactive antibodiesOPAopsonophagocytic activitypneumococcal diseasepneumococcal vaccineStreptococcus pneumoniaeV114

Identifiers

PMID37529944
PMCPMC10399465
OpenAlexW4385476552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.